4.08
-0.10 (-2.39%)
| Penutupan Terdahulu | 4.18 |
| Buka | 4.17 |
| Jumlah Dagangan | 451,708 |
| Purata Dagangan (3B) | 606,410 |
| Modal Pasaran | 332,021,856 |
| Harga / Jualan (P/S) | 2.93 |
| Harga / Buku (P/B) | 4.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 31 Oct 2024 |
| Margin Keuntungan | -149.47% |
| Margin Operasi (TTM) | -271.59% |
| EPS Cair (TTM) | -0.980 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -55.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 119.88% |
| Nisbah Semasa (MRQ) | 3.72 |
| Aliran Tunai Operasi (OCF TTM) | -55.42 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -31.16 M |
| Pulangan Atas Aset (ROA TTM) | -30.06% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.53% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Codexis, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -4.0 |
| Purata | -2.75 |
|
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.49% |
| % Dimiliki oleh Institusi | 83.39% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | - | 1.71 | -514,341 | -871,060 |
| Jumlah Keseluruhan Kuantiti Bersih | -514,341 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -871,060 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 1.71 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 01 Dec 2025 | Jual (-) | 253,533 | 1.65 | 418,329 | |
| OPALEYE MANAGEMENT INC. | 28 Nov 2025 | Jual (-) | 107,490 | 1.73 | 185,958 | |
| OPALEYE MANAGEMENT INC. | 26 Nov 2025 | Jual (-) | 153,318 | 1.74 | 266,773 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Nov 2025 | Pengumuman | Codexis Announces Signing of Lease for GMP Manufacturing Facility |
| 06 Nov 2025 | Pengumuman | Codexis Reports Third Quarter 2025 Financial Results |
| 29 Oct 2025 | Pengumuman | Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing |
| 23 Oct 2025 | Pengumuman | Codexis to Report Third Quarter 2025 Financial Results on November 6 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |